drugset / Trial / NCT06370065
Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the efficacy and safety of Serplulimab combined with bevacizumab biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) patients
Timeline
- Start
- 2023-04-27
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 4.5 mg/kg | Intravenous |